Bioelectronic firm electroCore beats Q3 revenue estimates

electroCore,.

05/11/2025 21:59

Overview

electroCore Q3 revenue grows 33% yr/yr, beating analyst expectations

Company raises FY 2025 revenue guidance to $31.5 mln - $32.5 mln

Prescription sales growth driven by VA market and wellness products

Outlook

Company raises FY 2025 revenue guidance to $31.5 mln - $32.5 mln

Company expects to reach $12 mln in quarterly revenue by H2 2026

Company plans targeted sales and marketing investments for 2025

Result Drivers

VA MARKET GROWTH - Prescription sales in Veteran Affairs (VA) market drove revenue increase, with gammaCore and Quell Fibromyalgia showing strong growth

WELLNESS PRODUCTS - Truvaga wellness product sales hit record high, contributing to revenue growth

INCREASED SALES AND MARKETING - Greater investment in sales and marketing supported revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$8.69 mln
$7.84 mln (3 Analysts)
Q3 Net Income
-$3.41 mln
Q3 Operating Income
Beat
-$2.88 mln
-$3.22 mln (3 Analysts)
Q3 Pretax Profit
Miss
-$3.41 mln
-$3.23 mln (3 Analysts)
Q3 Gross Profit
$7.47 mln
Q3 Operating Expenses
$10.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for electroCore, Inc. is $23.40, about 78.8% above its November 4 closing price of $4.95

Press Release: ID:nGNX69fmNG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)